We aimed to investigate potential differences in progression free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) compared to those with KRAS mutated (mut) tumours, in patients with KRAS G12C compared to patients with KRAS wt and KRAS non-G12C mutations, and among KRAS mutation subtypes. Here, KRAS is linked to neoplasm.